So far, only one retrospective analysis showed a possible correlation between the cutaneous side effects panniculitis and vitiligo-like lesions and the treatment outcome upon the BRAF plus MEK inhibitor combination dabrafenib and trametinib (11). This evidence concerns the gene BRAF and panniculitis.